The Online Investor
Medical Instruments & Supplies M&A image Medical Instruments & Supplies M&A » By The Online Investor Staff, updated Thu., Mar. 28, 11:28 AM Recent mergers and acquisitions in the Medical Instruments & Supplies M&A category.

Slide #39. AtriCure Endoscopic Technologies, Inc. d/b/a Estech

Acquirer: AtriCure (NASDAQ:ATRC)
Acquiree: Endoscopic Technologies, Inc. d/b/a Estech
Details: AtriCure, Inc. (NASDAQ:ATRC), a leading Atrial Fibrillation (Afib) medical device provider, and Endoscopic Technologies, Inc. d/b/a Estech ("Estech"), today announced that they have entered into a definitive merger agreement under which AtriCure has agreed to acquire Estech for a cash-free, debt-free up-front payment of approximately 2.1 million shares or $34 million of AtriCure common stock and up to $26 million in additional consideration based on the achievement of certain revenue-based milestones. The transaction is subject to customary closing conditions and is expected to close in the next several weeks. AtriCure shareholder approval is not required.

AtriCure provides treatments for atrial fibrillation (Afib), left atrial appendage management and post-operative pain. Co.'s ablation and left atrial appendage management products are used by physicians during both open-heart and minimally invasive procedures. Co.'s Isolator® Synergy™ Ablation System is approved by U.S. Food and Drug Administration (FDA) for the treatment of persistent and long-standing persistent Afib concomitant to other open-heart surgical procedures. The EPi-Sense® system is approved by FDA to treat patients with long-standing persistent Afib. All of Co.'s other ablation devices are cleared for sale in U.S., including its other radio frequency and cryoablation products.

ATRC SEC Filing Email Alerts Service


Open the ATRC Page at The Online Investor »

Company Name: 
AtriCure Inc
Website: 
www.atricure.com
Sector: 
Medical Instruments & Supplies
Number of ETFs Holding ATRC: 
29
Total Market Value Held by ETFs: 
$194.35M
Total Market Capitalization: 
$1.38B
% of Market Cap. Held by ETFs: 
14.09%
 

Open the ATRC Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree ATRC Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.67 out of 4)
67th percentile
(ranked higher than approx. 67% of all stocks covered)

Analysts' Target Price:
ATRC Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Medical Instruments & Supplies M&A - Slide 39 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.